ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,433.76
0.63%
Dow Jones
39,454.00
0.17%
Gold vs US Dollar
2,369.41
0.96%
Brent Oil
82.705
-1.48%
Bitcoin
60,568.65
-3.93%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX
  6. Cel Sci Corporation New (CVM)

  7. Cel Sci Corporation New (CVM) News

Cel Sci (CVM)

Cel Sci Corporation New
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:CVM
DateTimeSourceHeadlineSymbolCompany
10/05/202414:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
09/05/202418:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
09/05/202414:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
08/05/202414:00Business WireCEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck CancerAMEX:CVMCel Sci Corporation New
23/04/202414:00Business WireCEL-SCI Appoints Mario Gobbo to Its Board of DirectorsAMEX:CVMCel Sci Corporation New
19/03/202413:00Business WireCEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in ImmunologyAMEX:CVMCel Sci Corporation New
07/03/202416:33Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialAMEX:CVMCel Sci Corporation New
07/03/202416:33Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersAMEX:CVMCel Sci Corporation New
07/03/202416:31Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:CVMCel Sci Corporation New
06/03/202413:45Business WireCEL-SCI Corporation Issues Letter to ShareholdersAMEX:CVMCel Sci Corporation New
15/02/202413:00Business WireCEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial ResultsAMEX:CVMCel Sci Corporation New
14/02/202421:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:CVMCel Sci Corporation New
13/02/202417:00Business WireCEL-SCI Announces Closing of $7.75 Million Public Offering of Common StockAMEX:CVMCel Sci Corporation New
09/02/202413:44Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:CVMCel Sci Corporation New
09/02/202413:30Business WireCEL-SCI Announces Pricing of $7.75 Million Public Offering of Common StockAMEX:CVMCel Sci Corporation New
06/02/202414:00Business WireCEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer DrugAMEX:CVMCel Sci Corporation New
31/01/202414:00Business WireEuropean Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®AMEX:CVMCel Sci Corporation New
02/01/202414:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
02/01/202414:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
02/01/202414:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
22/12/202321:01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansAMEX:CVMCel Sci Corporation New
22/12/202313:00Business WireCEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate DevelopmentsAMEX:CVMCel Sci Corporation New
21/12/202321:15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]AMEX:CVMCel Sci Corporation New
04/12/202313:30Business WireUK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck CancerAMEX:CVMCel Sci Corporation New
20/11/202322:25Edgar (US Regulatory)Form 8-K - Current reportAMEX:CVMCel Sci Corporation New
20/11/202321:15Business WireCEL-SCI Announces Closing of $5 Million Public Offering of Common StockAMEX:CVMCel Sci Corporation New
16/11/202313:39Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:CVMCel Sci Corporation New
16/11/202313:30Business WireCEL-SCI Announces Pricing of $5 Million Offering of Common StockAMEX:CVMCel Sci Corporation New
30/10/202321:01Edgar (US Regulatory)Form 8-K - Current reportAMEX:CVMCel Sci Corporation New
30/10/202313:20Business WireCEL-SCI Issues Letter to ShareholdersAMEX:CVMCel Sci Corporation New
 Showing the most relevant articles for your search:AMEX:CVM

Your Recent History

LSE
POS
Plexus
LSE
TERN
Tern
LSE
SYME
Supply@me Capital
LSE
PET
Petrel Resources
LSE
AAZ
Anglo Asian Mining
LSE
SFOR
S4 Capital
LSE
ITV
Itv
LSE
RR.
Rolls-royce
LSE
THG
Thg
LSE
AGL
Angle
LSE
BOO
Boohoo
LSE
POLX
Polarean Imaging
LSE
TXP
Touchstone Exploration
LSE
PANR
Pantheon Resources
LSE
CHLL
Chill Brands
LSE
GDR
Genedrive
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved